Peregrine Pharmaceuticals CEO Nicholas Green receives $2.8M in 2021

Peregrine Pharmaceuticals reports 2021 executive compensation

By ExecPay News

Published: August 27, 2021

Peregrine Pharmaceuticals reported fiscal year 2021 executive compensation information on August 27, 2021.
In 2021, four executives at Peregrine Pharmaceuticals received on average a compensation package of $1.5M, a 83% increase compared to previous year.
Average pay of disclosed executives at Peregrine Pharmaceuticals
Nicholas S. Green, Chief Executive Officer, received $2.8M in total. 38% of Green's compensation, or $1.1M, was in stock awards. Green also received $138K in bonus, $723K in non-equity incentive plan, $347K in option awards, $421K in salary, as well as $127K in other compensation.
For fiscal year 2021, the median employee pay was $104,222 at Peregrine Pharmaceuticals. Therefore, the ratio of Nicholas S. Green's pay to the median employee pay was 27 to one.
Daniel R. Hart, Chief Financial Officer, received a compensation package of $1.3M, which increased by 60% compared to previous year. 31% of the compensation package, or $424K, was in salary.
Mark R. Ziebell, General Counsel, earned $1.1M in 2021, a 3% decrease compared to previous year.
Richard B. Hancock, Chief Executive Officer, received $926K in 2021, which increases by 20% compared to 2020.
Peregrine Pharmaceuticals' fiscal year ends on April 30.

Related executives

Nicholas Green

Peregrine Pharmaceuticals

Chief Executive Officer

Richard Hancock

Peregrine Pharmaceuticals

Chief Executive Officer

Daniel Hart

Peregrine Pharmaceuticals

Chief Financial Officer

Mark Ziebell

Peregrine Pharmaceuticals

General Counsel

You may also like

Source: SEC filing on August 27, 2021.